Edgewise Therapeutics (EWTX)
(Delayed Data from NSDQ)
$17.05 USD
-0.04 (-0.23%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $17.06 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
EWTX 17.05 -0.04(-0.23%)
Will EWTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EWTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EWTX
Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy
Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know
EWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
Other News for EWTX
Analysts Have Conflicting Sentiments on These Healthcare Companies: Insulet (PODD), Recursion Pharmaceuticals (RXRX) and Edgewise Therapeutics (EWTX)
Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (EWTX), Humacyte (HUMA) and Apellis Pharmaceuticals (APLS)
Edgewise Therapeutics (EWTX) Receives a Buy from Piper Sandler
Edgewise Therapeutics Unveils 2024 Equity Incentive Plan
Truist biotech analyst holds an analyst/industry conference call